Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations

Medicine, Molecular Biology, Oncology +14

Fusion of a Kinase Gene, <i>ALK</i> , to a Nucleolar Protein Gene, <i>NPM</i> , in Non-Hodgkin's Lymphoma

Stephan W. Morris, Mark N. Kirstein, Marcus B. Valentine et al. · Science · 1994 · 2.4K citations

Medicine, Genetics, Oncology +17

<i>ALK</i> Rearrangements Are Mutually Exclusive with Mutations in <i>EGFR</i> or <i>KRAS</i>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

Justin F. Gainor, Anna M. Varghese, Sai‐Hong Ignatius Ou et al. · Clinical Cancer Research · 2013 · 608 citations · Full text

Medicine, Molecular Genetics, Oncology +14

Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM)-ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1

Karen Pulford, Laurence Lamant, Stephan W. Morris et al. · Blood · 1997 · 566 citations

Medicine, Oncology, Pathology +17

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Thomas H. Marsilje, Wei Pei, Bei Chen et al. · Journal of Medicinal Chemistry · 2013 · 412 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +16